• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

4SC AG (FSE: VSC)

4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. 4SC’s pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development: resminostat and domatinostat. 4SC aims to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies and/or the eventual marketing and sales of approved drugs in select territories by 4SC itself. 4SC is headquartered in Planegg-Martinsried near Munich, Germany. The Company had 47 employees as of 31 March 2019 and is listed on the Prime Standard of the Frankfurt Stock Exchange (FSE Prime Standard: VSC; ISIN: DE000A14KL72). *

 

	Start	1997-01-01 established_pre
	Group	4SC (Group)
	Predecessor	4SC GmbH
	Industry	drug screening (HTS)
	Person	Loveridge, Jason (4SC 201609– CEO)
	Person 2	Doppler, Clemens (3i Germany 2007 Director Healthcare Team)
	Region	Martinsried
	Country	Germany
	Street	22 Fraunhoferstr.
	City	82152 Martinsried
	Tel	+49-89-700763-0
		Address record changed: 2018-07-24
Basic data	Employees	B: 11 to 50 (2019-03-31)
	Currency	EUR
	Annual sales	4,197,000 (revenue, consolidated (2017) 2017-12-31)
	Profit	-10,960,000 (2017-12-31)
	Cash	41,327,000 (2017-12-31)
		* Document for �About Section�: 4SC AG. (6/28/19). "Press Release: 4SC AG Secures EUR 11 Million from Capital Increase [Ad hoc, not for US, AU, CA, JP, ZA, et al.]". Planegg-Martinsried.
		Record changed: 2019-07-03

Advertisement

More documents for 4SC (Group)

• [1] 4SC AG. (6/28/19). "Press Release: 4SC AG Secures EUR 11 Million from Capital Increase [Ad hoc, not for US, AU, CA, JP, ZA, et al.]". Planegg-Martinsried....
• [2] 4SC AG. (3/20/19). "Press Release: 4SC AG Provides Results for Financial Year 2018 and Outlook". Planegg-Martinsried....
• [3] 4SC AG. (3/7/19). "Press Release: 9 Upcoming Conferences and Roadshows". Planegg-Martinsried....
• [4] 4SC AG. (2/6/19). "Press Release: First Patient Enrolled in Phase II Study EMERGE of Domatinostat (4SC-202) in Gastrointestinal Cancer". Planegg-Martinsried....
• [5] 4SC AG. (9/20/18). "Press Release: Domatinostat Plus Chemotherapy – Overcoming Drug Resistance". Planegg-Martinsried....
• [6] 4SC AG. (8/9/18). "Press Release: 4SC Provides Q2 and H1 2018 Update". Planegg-Martinsried....
• [7] Probiodrug AG. (4/23/18). "Press Release: Probiodrug Appoints Dr. Ulrich Dauer as Chief Executive Officer". Halle (Saale)....
• [8] 4SC AG. (4/19/18). "Press Release: Phase II Study of 4SC’s Resminostat in Biliary Tract Cancer in Japan Is Initiated". Planegg-Martinsried....
• [9] 4SC AG. (4/17/18). "Press Release: 4SC at AACR – Broadened Clinical Options for 4SC-202". Planegg-Martinsried....
• [10] 4SC AG. (4/11/18). "Press Release: Yakult Honsha Recruits First Japanese Patient in 4SC’s Pivotal RESMAIN Study of Resminostat in CTCL". Planegg-Martinsried....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2019. Made in Germany.